Adjuvant Treatment for Muscle-Invasive Bladder Cancer After Failure to Achieve Pathologic Response at Radical Cystectomy
This protocol addresses muscle-invasive bladder cancer (MIBC) T2–T4a cN0–1 M0 in patients eligible for cisplatin-based chemotherapy (eGFR > 40 mL/min) who have undergone perioperative treatment and radical cystectomy without achieving the required pathologic response.
Clinical Scenario
Muscle-invasive bladder cancer, clinical stage T2–T4a, cN0–1, M0. Non-metastatic disease managed with radical cystectomy. Patient eligible for cisplatin-based systemic therapy with glomerular filtration rate above 40 mL/min.
When Prior Treatment Did Not Reach Its Goal
This adjuvant protocol applies after perioperative cisplatin/gemcitabine and durvalumab — or neoadjuvant cisplatin-based combination chemotherapy — followed by radical cystectomy, when the required pathologic response was not achieved: specifically, when pathologic complete response (ypT0N0) or pathologic response (≤ ypT2N0) at radical cystectomy was not reached.
Adjuvant Approach
Following cystectomy without adequate pathologic downstaging, adjuvant cisplatin-based combination chemotherapy is the primary consideration — with specific eligibility criteria determining whether an alternative systemic approach applies. The complete selection criteria, sequencing logic, and qualifying conditions are available in the full protocol.
Clinical Goal
The primary aim is no disease recurrence at 6 months following adjuvant treatment.
References
- Offer perioperative chemoimmunotherapy with cisplatin/gemcitabine and durvalumab to patients with muscle-invasive bladder cancer (MIBC) (T2-T4a, cN0-1 M0) who are eligible for cisplatin-based chemotherapy (glomerular filtration rate > 40 mL/min allowed) and immunotherapy.
- Offer neoadjuvant cisplatin-based combination chemotherapy to patients with MIBC (T2-T4a, cN0 M0) who are eligible for cisplatin-based chemotherapy.
- Offer adjuvant cisplatin-based combination chemotherapy to patients with pT3/4 and/or pN+ disease if no neoadjuvant systemic therapy has been given.
- Offer adjuvant nivolumab to patients with high-risk muscle-invasive urothelial carcinoma (≥ ypT2N0 after NAC or pT3/4 and/or pN+) who are not eligible for, or who declined, adjuvant cisplatin-based chemotherapy.
- CheckMate 274, a phase III, double-blind RCT of adjuvant nivolumab versus placebo for up to one year in 709 patients with MIUC with a high risk of recurrence, demonstrated a significant improvement in median DFS.
View source ↗